ACPU
PDLI

Arrowgrass Capital Partners (US)’s PDL BioPharma, Inc. PDLI Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,022,951
Closed -$2.17M – 669
2016
Q4 		$2.17M Buy
+1,022,951
New +$2.85M 0.02% 358

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s PDLI Position: Q1 2017 in Review

Arrowgrass Capital Partners (US) sold out of PDL BioPharma, Inc. (PDLI) in Q1 2017, closing a stake of 1,022,951 shares — an estimated $2.17M sold.

Arrowgrass Capital Partners (US) first reported a position in PDLI in Q4 2016 and held it in 1 quarter. The position peaked at $2.17M in Q4 2016. 174 funds tracked by Wall St. Rank hold PDLI as of Q1 2017.

  • Arrowgrass Capital Partners (US) reported no remaining PDL BioPharma, Inc. position as of Q1 2017 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 1,022,951 PDL BioPharma, Inc. shares in Q1 2017, an estimated $2.17M.
  • Arrowgrass Capital Partners (US) first reported a position in PDL BioPharma, Inc. in Q4 2016 and held it in 1 quarter.
  • Arrowgrass Capital Partners (US)'s PDL BioPharma, Inc. position peaked at $2.17M in Q4 2016.
  • 174 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2017.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q1 2017, filed 15 May 2017.